Biotechnology

Insilico Medicine's AI-designed drug, ISM8969, enters human trials, targeting chronic neuroinflammation by crossing the elusive blood-brain barrier.

As giants rule the obesity market, small-cap MetaVia pitches a novel dual-agonist and a first-in-class MASH drug. Can its science win the day?

Verastem Oncology's combo therapy posts impressive early data in a notoriously deadly cancer, revealing a shrewd strategy for tackling drug resistance.

A landmark grant and trial expansion signal a pivotal shift in Parkinson's research, blending genetic targeting, global collaboration, and digital health.

With a promising drug and a fortified war chest, Trevi Therapeutics’ upcoming conference tour is a calculated move to conquer a vast, unmet medical need.

With a new $400M debt facility, Dyne Therapeutics is accelerating two promising drugs for DMD and DM1, showcasing the power of strategic, non-dilutive financing.

Gene therapy firm uniQure plans a 2026 FDA submission for AMT-130, a potential first disease-modifying treatment for Huntington's, on an accelerated track.

New research reveals that custom 3D braces can actively correct spinal curves, not just prevent them from worsening. This paradigm shift in non-surgical care offers new hope.

21 doctors from one practice in a "Top Doctors" Hall of Fame is a headline. But what does it reveal about building trust and innovation in cancer care?

Choosing the wrong regulatory partner can derail a market launch. A new guide from Q&C Services offers a veteran's roadmap for de-risking expansion.

Azitra is betting its future on a radical pivot, leveraging its science for cosmetics and biotech tools. Is this a savvy move for faster cash or a risky dilution of focus?

At BIO 2026, Israeli biotech Can-Fite seeks crucial partnerships for its late-stage cancer and inflammation drugs, built on a unique, safety-focused platform.

New data on ersodetug reveals a calculated strategy to conquer hyperinsulinism, balancing patient hope with the harsh realities of the biotech market.

Aker BioMarine's pact with ENGIE isn't just about PR. It's a move to hourly clean energy matching, a strategic play that redefines operational sustainability.

A new survey reveals the deep toll of canine skin allergies on pets and owners, exposing a massive unmet need that has pharmaceutical giants racing for a cure.

ARMR Sciences reports a major breakthrough in the fight against overdose, but can a preventative vaccine truly turn the tide on the fentanyl crisis?

Adaptive Biotechnologies' sophisticated convertible note offering isn't just about capital; it's a strategic de-risking of its finances to accelerate its fight against cancer.

A new collaboration aims to weaponize the immune system against tough GI cancers. We break down the science, strategy, and nearly $800M per program deal.

Researchers at Children's Hospital of Philadelphia have pioneered a personalized cartilage graft that could revolutionize surgery for a life-threatening infant airway condition.

FiberSense AG’s new 28-day CGM sensor just won European approval, challenging market leaders. But the real growth signal is its plan to move beyond glucose.